Bio & Pharma
Bridge Biotherapeutics, Pinotbio develop lung cancer treatment
Both companies will jointly look for candidate medicines for antibody-drug conjugates
By Jan 27, 2023 (Gmt+09:00)
1
Min read
Most Read
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Bridge Biotherapeutics, Pinotbio develop lung cancer treatment](https://www.kedglobal.com/data/ked/image/2023/01/27/ked202301270002.600x.0.jpg)
South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (ADC) for treating lung cancer, adding that they will seek candidate medicines for new ADCs over the next two years.
ADCs are next-generation antibody drugs and a new drug technology that has grabbed the spotlight of the global pharmaceutical industry. This anticancer drug attaches a chemical payload (drug) to an antibody and brings it to a target cancer cell.
If Bridge Biotherapeutics provides a "target" for lung cancer, Pinotbio will cooperate by linking the target to a drug using its own platform. In October last year, Pinotbio also signed a contract with drugmaker Celltrion of South Korea to discover drug candidates for ADCs.
Write to Jae-Young Han at jyhan@hankyung.com
More to Read
-
Bio & PharmaCelltrion increases its stake in British ADC developer Iksuda
Jan 25, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaSamjin Pharm to undertake joint ADC R&D with Novelty Nobility
Jan 04, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaLegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
Dec 23, 2022 (Gmt+09:00)
1 Min read
Comment 0
LOG IN